This is a reply to a recently published Commentary: “Palmitoylethanolamide: problems regarding micronization, ultra-micronization and additives” Inflammopharmacology DOI:10.1007/s10787-014-0202-3, written in relation to our review article: Skaper SD, Facci L, Fusco M, della Valle MF, Zusso M, Costa B, Giusti P (2014) “Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain” Inflammopharmacology 22:79–94 DOI:10.1007/s10787-013-0191-7. We believe that the Commentary by Kriek contains a number of erroneous statements and misinterpretations of the published scientific/medical literature which our reply shall elaborate on. Further, the writer of the Commentary has a direct connection to a company, JP Russell Science Ltd that sells palmitoylethanolamide. The take-home message of our review remains as originally stated: “Collectively, the findings presented here propose that palmitoylethanolamide merits further consideration as a disease-modifying agent for controlling inflammatory responses and related chronic and neuropathic pain”.

Skaper, S., Facci, L., Fusco, M., della Valle, M., Zusso, M., Costa, B., et al. (2015). Reply to: “Palmitoylethanolamide: problems regarding micronization, ultra-micronization and additives” Inflammopharmacology DOI:10.1007/s10787-014-0202-3. INFLAMMOPHARMACOLOGY, 23(2-3), 127-130 [10.1007/s10787-014-0208-x].

Reply to: “Palmitoylethanolamide: problems regarding micronization, ultra-micronization and additives” Inflammopharmacology DOI:10.1007/s10787-014-0202-3

Costa B.;
2015

Abstract

This is a reply to a recently published Commentary: “Palmitoylethanolamide: problems regarding micronization, ultra-micronization and additives” Inflammopharmacology DOI:10.1007/s10787-014-0202-3, written in relation to our review article: Skaper SD, Facci L, Fusco M, della Valle MF, Zusso M, Costa B, Giusti P (2014) “Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain” Inflammopharmacology 22:79–94 DOI:10.1007/s10787-013-0191-7. We believe that the Commentary by Kriek contains a number of erroneous statements and misinterpretations of the published scientific/medical literature which our reply shall elaborate on. Further, the writer of the Commentary has a direct connection to a company, JP Russell Science Ltd that sells palmitoylethanolamide. The take-home message of our review remains as originally stated: “Collectively, the findings presented here propose that palmitoylethanolamide merits further consideration as a disease-modifying agent for controlling inflammatory responses and related chronic and neuropathic pain”.
Articolo in rivista - Articolo scientifico
Excipients; Micronization; Neuropathic pain; Palmitoylethanolamide; Animals; Endocannabinoids; Ethanolamines; Humans; Neuralgia; Palmitic Acids;
English
2015
127
130
4
Skaper, S., Facci, L., Fusco, M., della Valle, M., Zusso, M., Costa, B., et al. (2015). Reply to: “Palmitoylethanolamide: problems regarding micronization, ultra-micronization and additives” Inflammopharmacology DOI:10.1007/s10787-014-0202-3. INFLAMMOPHARMACOLOGY, 23(2-3), 127-130 [10.1007/s10787-014-0208-x].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/296441
Citazioni
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
Social impact